Researchers at Johns Hopkins University have identified a potential new strategy for treating group 3 medulloblastoma, a highly aggressive and difficult-to-treat pediatric brain cancer. In mouse experiments, disrupting how tumor cells generate energy through fructose metabolism boosted the immune system's ability to fight the cancer. The findings were published in Acta Neuropathologica Communications and conducted at the Kimmel Cancer Center.
The study focused on the role of fructose metabolism in cancer cell growth. Unlike normal cells, cancer cells often rely on alternative energy sources, including fructose. By blocking a key enzyme involved in fructose metabolism, the researchers observed reduced tumor growth and increased activation of immune cells. This suggests that combining metabolic inhibitors with immunotherapies could offer a more effective treatment for children with this devastating disease.
Group 3 medulloblastoma accounts for about 25% of all medulloblastoma cases and has the worst prognosis, with a five-year survival rate of less than 50%. Current treatments, including surgery, radiation, and chemotherapy, often cause long-term side effects in young patients. The Johns Hopkins team hopes that targeting metabolism could provide a less toxic alternative.
The research also aligns with efforts by for-profit firms like CNS Pharmaceuticals Inc. (NASDAQ: CNSP), which is developing next-generation treatments for glioblastoma and other brain cancers. While CNS Pharmaceuticals focuses on different mechanisms, the broader interest in metabolic vulnerabilities underscores the potential of this approach.
The Johns Hopkins team plans to further investigate how fructose metabolism affects immune surveillance and whether combining metabolic inhibitors with existing immunotherapies can improve outcomes. The study was supported by grants from the National Institutes of Health and other foundations.
This breakthrough highlights the importance of understanding cancer metabolism in developing new therapies. For more information on the research, visit the Acta Neuropathologica Communications website.
